Open Access

Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi

  • Wenyu Shao1,
  • Chengjun Sui3,
  • Zhenyu Liu3,
  • Jiamei Yang3 and
  • Yanming Zhou2, 3Email author
Contributed equally
World Journal of Surgical Oncology20119:2

https://doi.org/10.1186/1477-7819-9-2

Received: 4 September 2010

Accepted: 8 January 2011

Published: 8 January 2011

Abstract

Background

To investigate the surgical outcome of hepatocellular carcinoma (HCC) patients with biliary tumor thrombi (BTT).

Methods

Surgical outcome of 27 HCC patients with BTT (group I) were compared with randomly selected HCC patients without BTT (group II; n = 270).

Results

One patient in group I died of hepatic failure within 30 days after resection. The 1-, 3- and 5-year cumulative survival rates of group I were 70.3%, 25.9%, and 7.4%, respectively; these were significantly lower than those of group II (90.6%, 54.0%, and 37.7%) (P < 0.001). The rates of early recurrence (≤ 1 year) after resection were significantly higher in group I than group II (70.3% vs. 34.8%) (P < 0.001).

Conclusion

HCC patients with BTT had a worse prognosis after resection than those without BTT. Resection should be considered for these tumors given the lack of effective alternative therapies.

Background

Hepatocellular carcinoma (HCC), one of the most common malignancies worldwide, can frequently invade the portal vein and cause portal vein tumor thrombus. By contrast, biliary tumor thrombi (BTT) is rare, and the incidence ranging from 0.53% to 12.9% in autopsy and surgical specimens [14]. HCC patients with BTT have a poor prognosis. Nonsurgical treatment modalities, such as transcatheter arterial chemoembolization (TACE), internal biliary stenting, radiotherapy, often has disappointing outcomes. Surgical treatment is the only way that possibly cures the patients. However, the role of hepatic resection in such patients is controversial [2, 57].

The aim of the present study was to investigate the surgical outcome of HCC patients with BTT by comparing with those without BTT.

Methods

Patients

From January 2000 to December 2006, 1246 patients underwent hepatic resections for HCC, at the Department of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, and Department of Special Treatment and Liver transplantation in Eastern Hepatobiliary Surgery Hospital of Second Military Medical University. Among them, 27 patients were found having BTT (group I). According to classification proposed by Esaki et al. [8], three patients (11.1%) had microscopic BTT and 24 patients (88.9%) had macroscopic BTT. For comparison of surgical results, 270 patients were randomly chosen from the remaining 1,219 HCC patients without BTT and matched 10:1 with group I by age, sex, concomitant liver background, and resection margins (group II).

Routine imaging studies included chest radiography, abdominal ultrasonography, and abdominal computed tomography. Endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography were employed to evaluate the extension of a BTT. Evaluation of liver function included serum biochemistry, prothrombin time. Serum hepatitis B surface antigen (HBsAg) and hepatitis C antibody were used as the positive markers of chronic viral hepatitis infection. HCC was diagnosed by at least two radiologic imaging showing characteristic features of HCC; or one radiologic imaging showing characteristic features of HCC associated with alpha-fetoprotein (AFP) > 400 ng/ml; or cytologic/histologic evidence [9]. Operative procedures were determined by preoperative diagnosis of location of the primary tumors and the extension of BTT.

Tumor size was measured directly in the surgical specimen by pathology examination. A tumor satellite is defined as any daughter tumor < 3 cm in size lying within a 3-cm zone from the dominant tumor [10]. The histological differentiation of HCC was graded according to the criteria of Edmondson and Steiner (G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated) [11]. Macrovascular invasion was defined as gross invasion of the right or left main branches of the portal vein or the hepatic veins [12]. Microvascular invasion indicated the presence of clusters of cancer cells floating in the vascular space line by endothelial cells on histopathologic examination [13]. The diagnosis of liver cirrhosis was based on the histology.

Perioperative deaths were defined as either within 30 days of surgery or occurring in hospital.

This retrospective study was approved by the ethics committee of the two hospitals.

Follow-up

After discharge, patients were followed-up every one month by AFP analysis and ultrasound or computed tomography at least every three months at our outpatient clinic, especially during the first two years. Patients who developed recurrence were treated with re-resection whenever possible, or by TACE, percutaneous ethanol injection, or radiofrequency ablation as appropriate. According to point of recurrences time from the date of hepatectomy, recurrences were classified into early (≤ 1 year) and late (> 1 year) recurrences [14].

Statistical analysis

Categorical and continuous variables were compared with chi-square test and t test, respectively. Overall survival rates were estimated with the Kaplan-Meier product-limit method and compared by log-rank test. All statistical analyses were performed using SPSS for Windows (version 11.0; SPSS Institute, Chicago, IL, USA). P < 0.05 was considered statistically significant.

Results

Patients features

The clinical data are presented in Table 1. Compared with groups II, group I patients had a higher incidence of carbohydrate antigen19-9 (CA19-9) > 37 U/ml, higher serum levels of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP) (P < 0.001). There were no differences in age, sex, serology for viral hepatitis, and serum albumin levels among the two groups. Patients with serum AFP levels greater than 400 ng/ml were found more frequently in the group I than in the groups II, but this result did not reach statistical significance (P = 0.058).
Table 1

Clinical features between two groups

Variables

Group I (n = 27)

Group II (n = 270)

P value

Age (years))

47.1 ± 10.5

48.0 ±11.3

0.272

Sex (Male/Female)

24/3

232/38

0.670

HBsAg-positive

26 (96.7%)

254 (94.1%)

0.636

Anti-HCV-positive

0

2 (1.2%)

0.654

Serum AFP (> 400 ng/ml)

16 (59.3%)

109 (40.3%)

0.058

Serum CA19-9 (> 37 U/ml)

13 (48.1%)

24 (8.8%)

< 0.001

Serum total bilirubin (umol/L)

116.4 ± 135.4

14.5 ± 7.8

< 0.001

Serum ALT (IU/L)

132.2 ± 107.9

59.6 ± 53.0

< 0.001

Serum AST (IU/L)

95.58 ± 51.5

60.1 ± 53.8

< 0.001

Serum albumin (g/L)

40.4 ± 4.92

41.8 ± 5.6

0.326

Serum GGT (IU/L)

583.1 ± 372.4

122.9 ± 134.1

< 0.001

Serum ALP (IU/L)

305.4 ± 148.0

132.2 ± 83.1

< 0.001

HBsAg: hepatitis B surface antigen. HCV: hepatitis C virus. AFP: alpha-fetoprotein.

CA19-9: carbohydrate antigen19-9. BTT: biliary tumor thrombi.

ALT: alanine aminotransferase. AST: aspartate aminotransferase. GGT: γ-glutamyl transpeptidase.

ALP: alkaline phosphatase.

Pathologic features

The pathologic features of HCC patients with or without BTT underwent hepatic resection are shown in Table 2. The incidence of tumor size ≤ 5 cm tended to be higher in group I, but this result did not reach statistical significance (P = 0.091). The incidence of microscopic vascular invasion, tumor capsule absence, and high Edmondson- Steiner grade in group I was significantly higher than that in group II (P < 0.05). There were no significant differences between the two groups with respect to cirrhosis, resection margins, macroscopic vascular invasion, lymph node metastasis, and tumor satellites.
Table 2

Comparison of pathologic features between group I and II

Variables

Group I (n = 27)

Group II (n = 270)

P value

Cirrhosis

18 (66.7%)

161 (59.6%)

0.476

Tumor size ≤ 5 cm

17 (62.9%)

124 (41.4%)

0.091

Resection margins ≤ 1 cm

3 (11.1%)

32 (11.8%)

0.909

Macrovascular invasion

3 (11.1%)

26 (9.6%)

0.805

Microvascular invasion

17 (62.9%)

116 (43.0%)

0.046

Lymph node metastasis

1 (3.7%)

8 (2.9%)

0.830

Tumor satellites

5 (18.5%)

42 (15.6%)

0.688

Tumor capsule absence

21 (77.7%)

142 (52.6%)

0.012

Edmonson-Steiner grade

   

1-2

1 (3.7%)

56 (20.1%)

0.036

3-4

26 (96.3%)

214 (79.9%)

 

Surgical results

The surgical procedures used in group I patients included right anterior resection (n = 1), right posterior resection (n = 2), right hepatectomy (n = 4), left hepatectomy (n = 8), left hepatectomy with caudate lobectomy (n = 1), left lateral recection (n = 3), left medial recection (n = 2), and partial resection (n = 6). The BTT were removed by the choledochotomy in 18 cases, from the cut end of the bile duct after liver resection in five cases, and en bloc removal with the primary tumor in three cases. Extrahepatic bile duct resection and biliaryenteric anastomosis was performed in one case.

One patient in group I died of hepatic failure within 30 days after resection. There was no perioperative mortality in group II. The 1-, 3- and 5-year cumulative survival rates of group I were 70.3%, 25.9%, and 7.4%, respectively; these were significantly lower than those of group II (90.6%, 54.0%, and 37.7%) (P < 0.001) (Figure 1).
Figure 1

Overall survival of patients in two groups. The overall survival of group I was lower than group II (P < .001).

During the median follow-up period of 39 months postresection (range 1 to 104 months), 25 of patients (92.5%) in group I and 218 patients (80.7%) in group II experienced intrahepatic recurrence. The rates of early recurrence (≤1 year) after resection were significantly higher in group I than group II (70.3% vs. 34.8%) (P < 0.001).

Seven patients in group I recurrenced with BTT again and had obstructive jaundice. One patient received re-resection, six were palliated with endoscopic stents.

Discussion

In 1949, Mallory et al. [15] described a single case of HCC invading the gall bladder and obstructing extrahepatic bile ducts. In 1975 Lin et al. [16] described eight patients and classified icteric type hepatoma. Since then, there are several reports concerning HCC with BDT have been published [17]. The outcome in patients who received palliative treatment was poor, with a mean survival time of less than 5 months [1719]. Surgical treatment is the only way that possibly cures the patients [19, 20]. However, the resectability rate of such tumors was very low in early reports, ranged only from 2% to 13.2% [21]. In recent years, with progress in imaging diagnosis and preoperative management, the number of resectable cases were increased remarkably [47, 21].

HCC invades into biliary system through one of the following three mechanisms: (1) the tumor may grow continuously in a distal fashion, filling the entire extrahepatic biliary system with a solid cast of tumor; (2) a fragment of necrotic tumor may separate from the proximal intraductal growth, migrating to the distal common bile duct and causing obstruction; or (3) hemorrhage from the tumor may partially or completely fill the biliary tree with blood clots [18]. Generally, the tumor thrombus was not adherent to the bile duct wall so it could be removed easily. Tumor thrombi rarely invade the walls of the large bile ducts around the hepatic hilus. Therefore, liver resection of the involved hepatic segments with thrombectomy through a choledochotomy is a rational technique for curative resection [2]. The indications for extrahepatic bile duct resection were macroscopic tumor invasion of the large bile ducts around the hepatic hilus [2].

Venous invasion is a well-established prognostic indicator of HCC [22, 23]. By contrast, whether BTT have a significant impact on the prognosis of HCC remain controversial. Shiomi et al. [2] reported that the 3- and 5-year survival rates were 47% and 28%, respectively, in 17 patients with BTT, similar to those achieved in 115 patients without BTT. Satoh et al. [5] also found that there were no significant differences in survival between patients with BTT and those without BTT. These data suggest that BTT in HCC patients might have lower aggressive potential and be less important as a prognostic factor. Paradoxically, Yeh et al. [6] in an analysis of 17 patients who underwent resection, reported that the overall survival was worse in patients with BTT, compared with those without BTT. In another recent study, Ikenaga et al. [7] reported that the median survival time of HCC patients with BTT after surgery was significantly shorter than that of those without thrombi (11.4 vs. 56.1 months, P = 0.002).

Currently, there are two surgical staging systems, which were developed based on the analysis of patients who received hepatic resection: one from the Liver Cancer Study Group of Japan (LCSGJ) and another from the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC). In LCSGJ system, presence of BTT was considered as an indicator of "advanced stage" of HCC. A study from Japan reported that the prognostic stratification ability of the LCSGJ staging system is superior to that of the AJCC/UICC staging system and that the BTT is the strongest prognostic factor for HCC [24]. This idea is supported by the results in our present study showing that the resection of HCC with BTT results in a significantly worse survival outcome compared with hepatic resection of HCC without BTT.

In current study, the incidence of microscopic vascular invasion [13, 23], tumor capsule absence [25, 26], high Edmondson- Steiner grade [22, 27, 28], and high level of GGT [29], unfavorable clinical prognostic factors, in group I were significantly higher than the respective factors in group II. Therefore, these factors may account for the poor prognosis in patients with BTT, at least in part. In addition, the incidences of CA19-9 > 37 U/ml, elevation of total bilirubin, ALT, AST, and ALP in group I were significantly higher than those in group II, which may be related to obstructive jaundice caused by BTT.

Previous studies have indicated that the HCC patients with BTT had smaller tumors and a higher percentage of a tumor size ≤ 5 cm than those without BTT [6]. Similarly, in this study, the incidence of tumor size ≤ 5 cm tended to be higher in group I, despite this result did not reach statistical significance due to the small number of patients. Although the exact mechanism remains unknown, some authors have suggested that a BTT in HCC tends to grow faster than the primary tumor itself [4].

Tumor recurrence remains the major cause of death after resection for HCC [30, 31]. Despite similar treatments, the prognosis for patients with early recurrence was worse than that of patients with late recurrence [14]. Qin et al. [4] reported that 14 patients with BTT (14/28, 50.0%) were found intrahepatic HCC recurrence within 1 year after operation. Ikenaga et al. [7] reported that 53% of patients suffered recurrences in the remnant liver within 3 months after surgery. In current study, patients with BTT developed early recurrence after resection more frequently.

We found seven patients in group I recurrenced with BTT again. Recurrence in the liver remnant could results from either intrahepatic metastasis from the primary tumor or multicentric occurrence. Intrahepatic metastasis is an important mechanism of early intrahepatic recurrence after resection of HCC. Spreading via the portal vein is considered the main route of intrahepatic metastasis [14, 32]. In current study, 17 patients (62.9%) in the group I had microscopic vascular invasion. However, nine of the other ten cases without venous invasion also developed early recurrence. Similar results had been published previously by Ikenaga et al. [7], who found that two patients with BTT without portal vein invasion suffered multiple recurrences in the remnant liver. The authors speculate that HCC invasion biliary system may be another route of intrahepatic metastasis.

Esaki et al. [8] reported that HCC patients with macroscopic BTT had a better postoperative survival than patients with microscopic BTT. But Ikenaga et al. [7] found that the prognosis was similar between two groups. In current study, statistical analysis was limited by the too small population with microscopic BTT.

The experience with orthotopic liver transplantation (OLT) in patients with BTT is limited. There were only five cases reported in the English literatures [21, 33]. Of these patients, one died 20 months after OLT due to multiple intrahepatic recurrences, one developed carcinoma recurrence at the lower end of the common bile duct 27 months after OLT. The other three patients were alive without evidence of recurrence during the follow-up period (17.6 to 28.1 months). These results suggest that OLT may be a treatment option for HCC with BDT in selected cases.

Conclusions

HCC patients with BTT had a worse prognosis after resection than those without BTT. Resection should be considered for these tumors given the lack of effective alternative therapies. Further studies are needed for understanding of molecular biology of BTT may yield therapeutic tools that can improve the prognosis of this subset of patients.

Consent

Written informed consent was obtained from the patients for publication of this case series. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Notes

Declarations

Authors’ Affiliations

(1)
Department of Liver Surgery, The First Affiliated Hospital of Nanjing Medical University
(2)
Department of Hepato-Biliary-Pancreato-Vascular Surgery, the First Affiliated Hospital of Xiamen University
(3)
Department of Special Treatment and Liver transplantation, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

References

  1. Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T: Hepatocellular carcinoma presenting as intrabile duct tumor growth. A clinicopathological study of 24 cases. Cancer. 1982, 49: 2144-2147. 10.1002/1097-0142(19820515)49:10<2144::AID-CNCR2820491026>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
  2. Shiomi M, Kamiya J, Nagino M, Uesaka K, Sano T, Hayakawa N, Kanai M, Yamamoto H, Nimura Y: Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. Surgery. 2001, 129: 692-698. 10.1067/msy.2001.113889.View ArticlePubMedGoogle Scholar
  3. Huang JF, Wang LY, Lin ZY, Chen SC, Hsieh MY, Chuang WL: Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol. 2002, 17: 190-195. 10.1046/j.1440-1746.2002.02677.x.View ArticlePubMedGoogle Scholar
  4. Qin LX, Ma ZC, Wu ZQ, Fan J, Zhou XD, Sun HC, Ye QH, Wang L, Tang ZY: Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. World J Gastroenterol. 2004, 10: 1397-1401.View ArticlePubMedGoogle Scholar
  5. Satoh S, Ikai I, Honda G, Okabe H, Takeyama O, Yamamoto Y, Yamamoto N, Iimuro Y, Shimahara Y, Yamaoka Y: Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery. 2000, 128: 779-783. 10.1067/msy.2000.108659.View ArticlePubMedGoogle Scholar
  6. Yeh CN, Jan YY, Lee WC, Chen MF: Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg. 2004, 28: 471-475. 10.1007/s00268-004-7185-y.View ArticlePubMedGoogle Scholar
  7. Ikenaga N, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K: Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 2009, 13: 492-497. 10.1007/s11605-008-0751-0.View ArticlePubMedGoogle Scholar
  8. Esaki M, Shimada K, Sano T, Sakamoto Y, Kosuge T, Ojima H: Surgical results for hepatocellular carcinoma with bile duct invasion: a clinicopathologic comparison between macroscopic and microscopic tumor thrombus. J Surg Oncol. 2005, 90: 226-232. 10.1002/jso.20260.View ArticlePubMedGoogle Scholar
  9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001, 35: 421-430. 10.1016/S0168-8278(01)00130-1.View ArticlePubMedGoogle Scholar
  10. Liau KH, Ruo L, Shia J, Padela A, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP: Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer. 2005, 104: 1948-1955. 10.1002/cncr.21415.View ArticlePubMedGoogle Scholar
  11. Edmondson HA, Steiner PE: Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer. 1954, 7: 462-503. 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
  12. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y, Lauwers GY, Vauthey JN, International Cooperative Study Group on Hepatocellular Carcinoma: Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005, 140: 450-457. 10.1001/archsurg.140.5.450.View ArticlePubMedGoogle Scholar
  13. Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW: Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000, 127: 603-608. 10.1067/msy.2000.105498.View ArticlePubMedGoogle Scholar
  14. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000, 89: 500-507. 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
  15. Mallory TB, Castleman B, Parris EE: Case records of the Massachusetts General Hospital. N Eng Med. 1947, 237: 673-676. 10.1056/NEJM194710302371805.View ArticleGoogle Scholar
  16. Lin TY, Chen KM, Chen YR, Lin WS, Wang TH, Sung JL: Icteric type hepatoma. Med Chi Dig. 1975, 4: 267-270.Google Scholar
  17. Lai ST, Lam KT, Lee KC: Biliary tract invasion and obstruction by hepatocellular carcinoma: report of five cases. Postgrad Med J. 1992, 68: 961-963. 10.1136/pgmj.68.806.961.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Chen MF, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC: Obstructive jaundice secondary to ruptured hepatocellular carcinoma into the common bile duct. Surgical experiences of 20 cases. Cancer. 1994, 73: 1335-1340. 10.1002/1097-0142(19940301)73:5<1335::AID-CNCR2820730505>3.0.CO;2-M.View ArticlePubMedGoogle Scholar
  19. Lau WY, Leung KL, Leung TW, Ho S, Chan M, Liew CK, Leung N, Johnson P, Li AK: Obstructive jaundice secondary to hepatocellular carcinoma. Surg Oncol. 1995, 4: 303-308. 10.1016/S0960-7404(10)80042-8.View ArticlePubMedGoogle Scholar
  20. Tantawi B, Cherqui D, Tran van Nhieu J, Kracht M, Fagniez PL: Surgery for biliary obstruction by tumour thrombus in primary liver cancer. Br J Surg. 1996, 83: 1522-1525. 10.1002/bjs.1800831109.View ArticlePubMedGoogle Scholar
  21. Peng SY, Wang JW, Liu YB, Cai XJ, Deng GL, Xu B, Li HJ: Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg. 2004, 28: 43-46. 10.1007/s00268-003-7079-4.View ArticlePubMedGoogle Scholar
  22. Haratake J, Takeda S, Kasai T, Nakano S, Tokui N: Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer. 1993, 72: 1178-1183. 10.1002/1097-0142(19930815)72:4<1178::AID-CNCR2820720408>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
  23. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC: Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol. 2007, 14: 2817-2823. 10.1245/s10434-007-9518-1.View ArticlePubMedGoogle Scholar
  24. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M: Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007, 245: 909-992. 10.1097/01.sla.0000254368.65878.da.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Franco D, Capussotti L, Smadja C, Bouzari H, Meakins J, Kemeny F, Grange D, Dellepiane M: Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology. 1990, 98: 733-738.PubMedGoogle Scholar
  26. Lai EC, Ng IO, Ng MM, Lok AS, Tam PC, Fan ST, Choi TK, Wong J: Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology. 1990, 11: 815-818. 10.1002/hep.1840110516.View ArticlePubMedGoogle Scholar
  27. Ng IO, Lai EC, Fan ST, Ng MM, So MK: Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer. 1995, 76: 2443-2448. 10.1002/1097-0142(19951215)76:12<2443::AID-CNCR2820761207>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
  28. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G, Tsurumaru M: Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 1993, 71: 19-25. 10.1002/1097-0142(19930101)71:1<19::AID-CNCR2820710105>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
  29. Zhou XD, Tang ZY, Yu YQ, Yang BH, Lu JZ, Lin ZY, Ma ZC, Zhang BH: Characteristics and prognosis of primary liver cancer in young patients in China. J Gastroenterol. 1995, 30: 632-635. 10.1007/BF02367790.View ArticlePubMedGoogle Scholar
  30. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP: Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003, 197: 753-758. 10.1016/j.jamcollsurg.2003.07.003.View ArticlePubMedGoogle Scholar
  31. Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J, Liu Z: Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol. 2010, 8: 55-10.1186/1477-7819-8-55.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Zhou YM, Yang JM, Li B, Yin ZF, Xu F, Wang B, Xu W, Kan T: Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int. 2010, 9: 33-37.PubMedGoogle Scholar
  33. Lee KW, Park JW, Park JB, Kim SJ, Choi SH, Heo JS, Kwon CH, Kim DJ, Han YS, Lee SK, Joh JW: Liver transplantation for hepatocellular carcinoma with bile duct thrombi. Transplant Proc. 2006, 38: 2093-2094. 10.1016/j.transproceed.2006.06.034.View ArticlePubMedGoogle Scholar

Copyright

© Shao et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement